Anticoagulation Reversal

Quick Answer

Anticoagulation reversal in the ICU is required for life-threatening bleeding or urgent surgery in patients on anticoagulant therapy. The choice of reversal strategy depends on the specific anticoagulant and clinical urgency. [1,2]

Warfarin (vitamin K antagonists):

• Vitamin K 5-10 mg IV (onset 6-24 hours)
• 4-factor prothrombin complex concentrate (4F-PCC) 25-50 U/kg (target INR below 1.5, onset 10-30 minutes)
• PCC is superior to FFP for rapid reversal with lower volume and faster correction [3,4]

Unfractionated heparin:

• Protamine sulfate 1 mg per 100 units UFH (maximum 50 mg)
• Dose based on time since last heparin dose
• Complete reversal achieved in most cases [5,6]

Dabigatran (direct thrombin inhibitor):

• Idarucizumab 5 g IV (two 2.5 g boluses) - specific reversal agent
• 100% reversal of anticoagulant effect within minutes (REVERSE-AD trial) [7,8]

Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban):

• Andexanet alfa (if available): Low dose (400 mg bolus + 480 mg infusion) or high dose (800 mg bolus + 960 mg infusion) based on timing/dose of last DOAC
• 4-factor PCC 50 U/kg if andexanet unavailable (ANNEXA-4 trial) [9,10]

Adjunctive therapy:

• Tranexamic acid 1 g IV loading + 1 g over 8 hours for ongoing bleeding (CRASH-2) [11]
• Activated charcoal 50 g if DOAC ingested within 2-4 hours
• Maintain fibrinogen greater than 1.5 g/L, platelets greater than 50 x 10^9/L (greater than 100 for CNS bleeding)

---

CICM Exam Focus

Key High-Yield Points

1. Warfarin reversal: 4F-PCC 25-50 U/kg achieves INR below 1.5 in 10-30 minutes; vitamin K 5-10 mg IV for sustained reversal (onset 6-24 hours) [3,4]
2. INR-based PCC dosing: INR 2-4: 25 U/kg; INR 4-6: 35 U/kg; INR greater than 6: 50 U/kg [12]
3. REVERSE-AD trial: Idarucizumab 5 g IV achieves 100% reversal of dabigatran within minutes; normal hemostasis in 92% requiring surgery [7,8]
4. ANNEXA-4 trial: Andexanet alfa reduces anti-Xa activity by 92%; hemostatic efficacy 82% at 12 hours; 10% thrombotic event rate [9,10]
5. Protamine dosing: 1 mg per 100 U UFH given in previous 2-3 hours; reduce dose if greater than 4 hours since heparin [5]
6. LMWH reversal: Protamine only 60% effective for enoxaparin; no specific reversal agent [13]
7. BRIDGE trial: Perioperative bridging in AF patients increases bleeding without reducing stroke risk; avoid routine bridging [14]
8. TXA timing: Must be administered within 3 hours of injury; greater than 3 hours may increase mortality (CRASH-2) [11,15]

Common Viva Themes

• Systematic approach to anticoagulant reversal in intracranial hemorrhage
• Comparison of reversal strategies: PCC vs FFP vs specific antidotes
• Perioperative management of anticoagulated patients
• Evidence base: REVERSE-AD, ANNEXA-4, INCH trial, BRIDGE trial
• Thrombotic risk after reversal and timing of anticoagulation resumption
• DOAC levels and when laboratory testing is useful

Common Pitfalls

• Forgetting vitamin K with PCC (PCC provides temporary reversal only; factors are consumed)
• Using FFP instead of PCC for urgent VKA reversal (slower, larger volume, incomplete correction)
• Not adjusting protamine dose for time since heparin (over-dosing causes anticoagulation)
• Treating elevated INR without bleeding (often does not require intervention)
• Ignoring thrombotic risk after reversal (10% thrombosis rate in ANNEXA-4)
• Missing dabigatran as dialyzable (useful if idarucizumab unavailable)
• Failing to address underlying cause of bleeding

---

Key Points

• Warfarin reversal: 4F-PCC 25-50 U/kg + vitamin K 5-10 mg IV; target INR below 1.5 [3,4]
• 4F-PCC superior to FFP: Faster correction (10-30 min vs 24-32 h), smaller volume, higher efficacy [3,16]
• Dabigatran: Idarucizumab 5 g IV provides complete, immediate reversal; dabigatran is dialyzable [7,8]
• Xa inhibitors: Andexanet alfa first-line if available; 4F-PCC 50 U/kg alternative [9,10]
• UFH: Protamine 1 mg per 100 U (max 50 mg); half-life consideration critical [5,6]
• LMWH: Protamine only 60% effective; consider PCC or rFVIIa for life-threatening bleeding [13]
• TXA: 1 g + 1 g for trauma; must be within 3 hours (CRASH-2) [11,15]
• Thrombosis risk: 5-10% after reversal; restart anticoagulation when safe [9,17]
• BRIDGE trial: Bridging increases bleeding without stroke benefit in AF patients [14]

---

Pharmacology of Anticoagulants

Classification and Mechanisms

Understanding anticoagulant mechanisms is essential for selecting appropriate reversal strategies.

Vitamin K Antagonists (Warfarin)

Warfarin inhibits vitamin K epoxide reductase (VKORC1), preventing regeneration of reduced vitamin K. This reduces hepatic synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins (C, S). The anticoagulant effect develops over 2-5 days as existing factors are depleted. Factor VII has the shortest half-life (6 hours), followed by IX (24 hours), X (36 hours), and II (60-72 hours). [18]

Clinical implications:

• INR primarily reflects factor VII initially
• Full anticoagulation requires depletion of factor II
• Reversal requires replacement of all four factors

Unfractionated Heparin (UFH)

UFH is a heterogeneous mixture of glycosaminoglycans (mean MW 15,000 Da) that binds antithrombin III, potentiating its inhibition of thrombin (IIa) and factor Xa. The ratio of anti-IIa to anti-Xa activity is approximately 1:1. UFH has a short half-life (30-90 minutes IV), dose-dependent clearance, and high protein binding, making its effect variable and requiring monitoring with aPTT or anti-Xa levels. [5,6]

Low-Molecular-Weight Heparin (LMWH)

LMWH (enoxaparin, dalteparin) consists of smaller heparin fragments (mean MW 4,000-5,000 Da) with preferential anti-Xa activity (anti-Xa:anti-IIa ratio 2:1 to 4:1). The longer half-life (3-6 hours) and more predictable pharmacokinetics allow fixed-dose subcutaneous administration without routine monitoring. However, this predictability comes at the cost of reduced reversibility. [13]

Direct Thrombin Inhibitors (Dabigatran)

Dabigatran etexilate is a prodrug converted to dabigatran, which directly inhibits free and clot-bound thrombin. It has 80% renal elimination, a half-life of 12-17 hours (prolonged in renal impairment), and does not require routine monitoring. Unlike warfarin, dabigatran provides immediate anticoagulation. [7,19]

Direct Factor Xa Inhibitors (Rivaroxaban, Apixaban, Edoxaban)

These agents directly inhibit factor Xa without requiring antithrombin as a cofactor. Key pharmacokinetic differences:

All have rapid onset (1-4 hours peak effect) and relatively short half-lives, making "watchful waiting" feasible in less urgent situations. [9,20]

Laboratory Assessment

Vitamin K Antagonists:

• INR: Standard monitoring; therapeutic range typically 2-3 (2.5-3.5 for mechanical valves)
• Factor assays rarely needed

UFH:

• aPTT: Traditional monitoring; target 1.5-2.5x control
• Anti-Xa (heparin) level: More accurate, less affected by factor deficiencies
• ACT: Used in cardiac surgery (target 400-480 seconds for CPB)

LMWH:

• Anti-Xa (LMWH): For monitoring if indicated (obesity, renal impairment, pregnancy)
• Peak 4 hours post-dose

Direct Oral Anticoagulants:

Critical points:

• Normal PT/INR does NOT exclude therapeutic Xa inhibitor levels (especially apixaban)
• Normal aPTT makes significant dabigatran effect unlikely
• Drug-specific assays are required for quantification
• Point-of-care tests (ROTEM, TEG) show non-specific changes [21,22]

---

Reversal Strategies

Warfarin Reversal

Vitamin K (Phytonadione)

Vitamin K is essential for sustained reversal of warfarin effect by restoring hepatic factor synthesis.

Dosing:

• Life-threatening bleeding: 5-10 mg IV slow infusion (over 30-60 minutes)
• Less urgent reversal: 1-5 mg IV or oral
• Oral and IV have equivalent efficacy; IV preferred in critical illness

Onset: 6-24 hours (new factor synthesis required)

Duration: Sustained reversal lasting days

Adverse effects:

• Anaphylactoid reactions (rare, usually with rapid IV administration)
• May make re-anticoagulation difficult for 1-2 weeks

Important: Always administer vitamin K with PCC for serious bleeding, as PCC factors are consumed and without vitamin K the anticoagulant effect will recur. [18,23]

Prothrombin Complex Concentrate (PCC)

PCC products contain concentrated vitamin K-dependent clotting factors. There are two types:

3-Factor PCC: Contains factors II, IX, X (minimal factor VII)

• Less effective for complete INR reversal
• Rarely used in modern practice

4-Factor PCC (Beriplex, Kcentra, Octaplex): Contains factors II, VII, IX, X plus protein C and S

• Preferred agent for VKA reversal
• Provides immediate, complete factor replacement [3,4,12]

Dosing (INR-based):

Alternative (fixed-dose): 25-50 U/kg regardless of INR

Administration: IV infusion at 3-8 mL/min (product-specific)

Onset: 10-30 minutes

Duration: Factor-dependent (shortest for VII); combined with vitamin K for sustained effect

Efficacy:

• INCH trial: 67% achieved INR ≤1.2 within 3 hours with PCC vs 9% with FFP (pbelow 0.0001) [4]
• Sarode et al: PCC superior to FFP for rapid INR reversal and hemostatic efficacy [3]

Adverse effects:

• Thrombotic events (1-8%): DIC, DVT, PE, MI, stroke
• Heparin-induced thrombocytopenia (some products contain heparin)
• Higher risk in patients with pre-existing thrombotic risk factors [12,24]

Fresh Frozen Plasma (FFP)

FFP contains all coagulation factors but has significant limitations:

Dosing: 15-30 mL/kg (typically 4-8 units in adults)

Limitations:

• Large volume (risk of TACO, pulmonary edema)
• Slow administration (2-4 hours for full dose)
• Variable factor content
• Requires ABO typing and thawing
• Incomplete INR correction in many cases [3,16]

Current role: Second-line when PCC unavailable; may be used adjunctively in massive hemorrhage

Recombinant Factor VIIa (rFVIIa)

Role: Not routinely recommended for VKA reversal

• Corrects INR but does not provide other factors
• High thrombotic risk
• Reserved for refractory bleeding when other options failed [25]

Heparin Reversal

Protamine Sulfate

Protamine is a basic protein derived from salmon sperm that forms inactive complexes with heparin.

Dosing for UFH reversal:

Maximum single dose: 50 mg (higher doses cause anticoagulation from protamine)

Administration: Slow IV over 10 minutes (rapid administration causes hypotension, bradycardia)

Efficacy: Near-complete reversal of UFH anticoagulant effect

Monitoring: Repeat aPTT or ACT 5-15 minutes post-administration [5,6]

Adverse effects:

• Hypotension (histamine release, especially with rapid infusion)
• Bradycardia
• Anaphylaxis (rare; higher risk in fish allergy, previous protamine exposure, vasectomy)
• Pulmonary vasoconstriction
• Rebound anticoagulation (protamine half-life shorter than some heparin fractions) [26]

LMWH Reversal

Protamine is less effective for LMWH due to the smaller molecular size:

Efficacy:

• Enoxaparin: ~60% reversal of anti-Xa activity
• Dalteparin: Similar partial reversal
• Does not neutralize anti-Xa activity of smallest LMWH fragments

Dosing (if below 8 hours since LMWH):

• 1 mg protamine per 1 mg enoxaparin (or per 100 anti-Xa units)
• Second dose of 0.5 mg/mg if bleeding continues

Alternatives for life-threatening LMWH-related bleeding:

• 4-Factor PCC 25-50 U/kg
• rFVIIa 90 mcg/kg (high thrombotic risk)
• Supportive care (blood products, TXA) [13,27]

Dabigatran Reversal

Idarucizumab (Praxbind)

Idarucizumab is a humanized monoclonal antibody fragment that binds dabigatran with 350-fold higher affinity than thrombin, effectively neutralizing the drug.

Mechanism: Acts as a "molecular sponge," binding free and thrombin-bound dabigatran without intrinsic procoagulant activity

Dose: 5 g IV administered as two 2.5 g boluses (no more than 15 minutes apart)

Onset: Immediate (within minutes)

Duration: 24 hours; may need re-dosing if dabigatran reabsorbed or ongoing ingestion [7,8]

REVERSE-AD Trial (PMID: 26559317):

• Design: Multicenter, prospective, open-label, single-arm study
• Population: 503 patients with life-threatening bleeding (Group A) or requiring urgent surgery (Group B)
• Results:
  • "Maximum reversal of dabigatran effect: 100% (median)"
  • "Normal hemostasis in urgent surgery: 92%"
  • "Time to cessation of bleeding: 11.4 hours (median) for Group A"
  • "Thrombotic events: 4.8% within 30 days (likely related to underlying condition, not drug)"

Key points:

• Does NOT require dose adjustment for renal impairment
• No procoagulant effect
• Very expensive (~$4,000-5,000 per dose)
• Limited availability in some centers [7,8]

Alternative Strategies

If idarucizumab unavailable:

Hemodialysis:

• Dabigatran is dialyzable (80% protein-unbound)
• 4-hour hemodialysis removes ~60% of drug
• Useful for overdose or severe renal impairment
• Impractical for acute bleeding (delay, vascular access)

Activated PCC (aPCC/FEIBA):

• 50-80 U/kg
• May provide some hemostatic benefit
• Higher thrombotic risk than specific antidote

4-Factor PCC:

• 50 U/kg
• Less evidence than for Xa inhibitors
• Consider as adjunct [28]

Factor Xa Inhibitor Reversal

Andexanet Alfa (Andexxa/Ondexxya)

Andexanet alfa is a modified recombinant factor Xa molecule that acts as a decoy receptor for factor Xa inhibitors.

Mechanism: Binds and sequesters Xa inhibitors with high affinity; also binds tissue factor pathway inhibitor (TFPI), potentially enhancing coagulation

Dosing (based on last DOAC dose):

Administration:

• Bolus over 15-30 minutes
• Followed by 2-hour infusion
• Total treatment time: 2.5 hours [9,10]

ANNEXA-4 Trial (PMID: 31479100):

• Design: Multicenter, prospective, open-label, single-arm study
• Population: 352 patients with major bleeding on Xa inhibitors (67% intracranial)
• Results:
  • "Anti-Xa activity reduction: 92% for both apixaban and rivaroxaban"
  • "Hemostatic efficacy (excellent/good): 82% at 12 hours"
  • "Thrombotic events: 10% within 30 days"
  • 30-day mortality: 14%

ANNEXA-I Trial (PMID: 38747214):

• First randomized trial comparing andexanet to usual care (mostly PCC) for ICH
• Results:
  • "Hemostatic efficacy: Superior with andexanet"
  • 30-day mortality: 10.3% vs 11.8% (not significantly different)
  • "Thrombotic events: Higher with andexanet (10.3% vs 5.6%)"

Limitations:

• Very expensive (~$25,000-50,000 per treatment)
• Limited availability
• Significant thrombotic risk
• No survival benefit demonstrated over PCC [9,10,29]

4-Factor PCC for Xa Inhibitor Reversal

When andexanet unavailable, 4F-PCC is the recommended alternative.

Mechanism: Provides procoagulant factors to overcome Xa inhibitor effect; does not directly reverse drug

Dosing: 50 U/kg (some protocols use 25-50 U/kg)

Evidence:

• Multiple observational studies show hemostatic efficacy
• ANNEXA-I found similar mortality outcomes to andexanet
• Lower cost and wider availability
• Lower thrombotic event rate than andexanet in some studies [10,30]

Recommendation: Given cost, availability, and similar outcomes, 4F-PCC is a reasonable first-line choice for Xa inhibitor reversal when andexanet is not readily available.

Activated Charcoal

If factor Xa inhibitor ingested within 2-4 hours, activated charcoal (50 g) may reduce absorption and subsequent anticoagulant effect. Most effective within 2 hours of ingestion. [31]

Adjunctive Therapies

Tranexamic Acid (TXA)

TXA is an antifibrinolytic that inhibits plasminogen activation, reducing fibrinolysis and stabilizing clot.

CRASH-2 Trial (PMID: 20554319):

• 20,211 trauma patients with significant hemorrhage
• TXA 1 g loading over 10 minutes + 1 g over 8 hours
• Results:
  • "All-cause mortality: 14.5% vs 16.0% (RR 0.91, p=0.0035)"
  • "Death due to bleeding: 4.9% vs 5.7% (RR 0.85, p=0.0077)"
• Critical finding: TXA must be given within 3 hours; administration greater than 3 hours increased mortality

Dosing:

• Trauma: 1 g IV loading + 1 g over 8 hours
• Surgical bleeding: 1 g IV (repeat as needed)
• Cardiac surgery: Various high-dose protocols

Role in anticoagulant reversal:

• Adjunctive therapy for ongoing bleeding
• Does not reverse anticoagulant effect
• May be particularly useful when specific reversal agents are delayed or unavailable [11,15,32]

Blood Product Support

Maintain hemostatic targets:

• Fibrinogen greater than 1.5 g/L (cryoprecipitate or fibrinogen concentrate)
• Platelets greater than 50 x 10^9/L (greater than 100 for CNS bleeding or ongoing hemorrhage)
• Hemoglobin as per clinical situation (avoid excessive transfusion)
• Correct hypothermia and acidosis [33]

---

Clinical Scenarios

Intracranial Hemorrhage

ICH on anticoagulation requires the most aggressive reversal strategy.

Warfarin-associated ICH:

1. 4F-PCC 50 U/kg IV immediately (do not wait for INR)
2. Vitamin K 10 mg IV over 20-30 minutes
3. Target INR below 1.5 within 4 hours (ideally below 1 hour)
4. Repeat INR at 30 minutes; additional PCC if needed
5. BP target below 140 mmHg systolic

DOAC-associated ICH:

1. Dabigatran: Idarucizumab 5 g IV immediately
2. Xa inhibitors:
   • Andexanet alfa (if available) OR
   • 4F-PCC 50 U/kg
3. Consider activated charcoal if ingestion below 4 hours
4. TXA 1 g IV as adjunct

Evidence from INCH trial (PMID: 27178157):

• PCC vs FFP in VKA-associated ICH
• PCC: 67% achieved INR ≤1.2 at 3 hours vs 9% FFP (pbelow 0.0001)
• PCC associated with smaller hematoma expansion
• Trial stopped early for PCC superiority [4,34]

Gastrointestinal Bleeding

Approach:

1. Assess severity and hemodynamic status
2. Determine time since last anticoagulant dose
3. Laboratory assessment (specific assays if available)
4. Reversal based on severity:
   • Life-threatening: Full reversal as per ICH protocol
   • Severe: Consider reversal vs supportive care
   • Moderate: Often supportive care with watchful waiting

DOAC consideration: Given short half-lives (12-17 hours), supportive care may be sufficient for less severe bleeding if last dose greater than 24-48 hours ago.

Timing of endoscopy: Early endoscopy (within 24 hours) for diagnosis and hemostasis; reversal should not delay urgent endoscopy if indicated. [35]

Perioperative Management

Elective Surgery

Warfarin:

• Stop 5 days before procedure (longer if INR supratherapeutic)
• Check INR day before surgery (target below 1.5 for most procedures)
• Resume 12-24 hours post-operatively when hemostasis assured

DOACs:

• Standard risk surgery: Stop 24-48 hours before (longer if renal impairment)
• High bleeding risk: Stop 48-72+ hours before
• No bridging required in most cases
• Resume when hemostasis assured (typically 24-72 hours) [36]

BRIDGE Trial (PMID: 26095867):

• 1,884 patients with AF on warfarin undergoing elective surgery
• Randomized to bridging (dalteparin) vs placebo
• Results:
  • "Thromboembolism: 0.4% no-bridging vs 0.3% bridging (non-inferior)"
  • "Major bleeding: 1.3% no-bridging vs 3.2% bridging (p=0.005)"
• Conclusion: Bridging increases bleeding without reducing stroke risk; avoid routine bridging in AF [14]

Exceptions (may warrant bridging):

• Mechanical heart valve (especially mitral)
• Recent VTE (below 3 months)
• Very high-risk thrombotic conditions
• Discuss with hematology/cardiology

Emergency Surgery

Assessment:

1. What anticoagulant and when was last dose?
2. Can surgery be delayed 12-24 hours?
3. What is the bleeding risk of surgery?
4. What reversal is available?

Decision framework:

Surgical hemostasis: Even with reversal, meticulous surgical hemostasis is essential; reversal agents do not eliminate bleeding risk. [36,37]

---

Thrombotic Risk After Reversal

Mechanism

Anticoagulant reversal creates a prothrombotic state:

• Underlying indication for anticoagulation still present
• Procoagulant factors from PCC
• Inflammatory/hemostatic response to bleeding
• Immobility and critical illness

Event Rates

Events include: MI, stroke, DVT, PE, catheter thrombosis [7,9,12]

Resumption of Anticoagulation

Timing depends on:

• Type of bleeding (CNS vs other)
• Hemostatic stability
• Underlying thrombotic risk
• Patient preferences

General guidance:

• GI bleeding: 7-14 days (after endoscopic hemostasis)
• ICH: 4-8 weeks (individualized, multidisciplinary discussion)
• Other major bleeding: When hemostasis assured (often 48-72 hours)
• Low-risk bleeding: May not require reversal at all [17,38]

---

Special Populations

Renal Impairment

Dabigatran: 80% renal elimination; prolonged half-life in renal failure

• eGFR below 30: Drug may persist for days
• Hemodialysis removes dabigatran effectively
• Idarucizumab effective regardless of renal function

Xa inhibitors: Variable renal elimination

• Rivaroxaban: 33% renal (longest half-life extension)
• Apixaban: 27% renal (safest in renal impairment among Xa inhibitors)
• Edoxaban: 50% renal

Warfarin: Not renally eliminated, but uremic platelet dysfunction complicates bleeding [39]

Liver Disease

Warfarin: Reduced synthesis of clotting factors; INR unreliable in liver disease

• Bleeding risk increased
• Reversal may require higher PCC doses

DOACs: Contraindicated in severe liver disease (Child-Pugh C)

• Variable hepatic metabolism
• Standard reversal applies when used in appropriate patients [40]

Obesity

DOACs: Fixed dosing may result in subtherapeutic levels in morbid obesity

• Drug levels may be lower than expected
• Consider measuring drug-specific anti-Xa levels
• Standard reversal dosing applies [41]

Cardiac Surgery

CPB management:

• UFH: ACT-guided (target 400-480 seconds)
• Protamine reversal: ACT or heparin concentration-guided
• Residual anticoagulation common cause of post-CPB bleeding

Preoperative DOACs:

• Ideally held 5+ days for on-pump surgery
• Emergency surgery: Use idarucizumab (dabigatran) or andexanet/PCC (Xa inhibitors)
• CPB may help clear some DOACs [6,42]

---

Monitoring Response

Laboratory Targets

Clinical Endpoints

• Cessation of active bleeding
• Hemodynamic stability
• Falling transfusion requirements
• Stable hemoglobin/hematocrit
• Successful surgery/procedure without excessive bleeding

Re-checking After Reversal

• INR: 30-60 minutes post-PCC; 6 hours post-vitamin K
• aPTT: 5-15 minutes post-protamine
• DOAC levels: Limited utility (if available, check 12-24 hours)
• Consider re-dosing if inadequate response and ongoing bleeding [21,22]

---

Cost and Availability

Comparative Costs (Approximate)

Practical Considerations

• Stock availability varies by institution
• After-hours access may be limited for specialized agents
• PCC is widely available and cost-effective alternative to andexanet
• Develop institutional protocols for anticoagulant reversal
• Blood bank collaboration essential [43]

---

Evidence Summary

Landmark Trials

Guidelines

---

CICM Exam Practice

SAQ 1: Warfarin-Associated Intracranial Hemorrhage

Question: A 72-year-old woman on warfarin for atrial fibrillation (target INR 2-3) presents with sudden onset headache and left-sided weakness. CT brain shows a 40 mL right frontoparietal intracerebral hemorrhage. Her INR is 3.2. BP is 185/95 mmHg.

(a) Outline your immediate management of the anticoagulation-related bleeding. (4 marks) (b) Compare the efficacy and safety of 4-factor prothrombin complex concentrate (PCC) versus fresh frozen plasma (FFP) for warfarin reversal in this setting. (4 marks) (c) Discuss the factors that influence timing of anticoagulation resumption after intracranial hemorrhage. (4 marks)

Model Answer:

(a) Immediate management (4 marks):

Anticoagulant reversal (do not wait for repeat INR):

1. 4-Factor PCC 25-50 U/kg IV (for INR 3.2, use 25-35 U/kg)

   • Provides immediate replacement of factors II, VII, IX, X
   • Onset within 10-30 minutes
   • Target INR below 1.5

2. Vitamin K 10 mg IV over 20-30 minutes

   • Essential for sustained reversal (PCC factors are consumed)
   • Provides substrate for ongoing hepatic factor synthesis
   • Onset 6-24 hours
   • Administer concurrently with PCC

3. Recheck INR at 30-60 minutes

   • Additional PCC if INR remains greater than 1.5

Blood pressure management:

• Target SBP below 140 mmHg (per INTERACT2 and ATACH-2)
• Labetalol or nicardipine infusion

Monitoring:

• Continuous neurological assessment
• Consider repeat CT if deterioration
• Neurosurgical consultation

(b) PCC vs FFP comparison (4 marks):

Evidence (INCH trial):

• PCC superior to FFP for INR normalization (67% vs 9%, pbelow 0.0001)
• Trial stopped early for PCC efficacy
• PCC associated with smaller hematoma expansion
• FFP now considered second-line only when PCC unavailable

Key point: FFP cannot achieve the rapid, complete reversal required in ICH. Volume constraints further limit its effectiveness.

(c) Anticoagulation resumption factors (4 marks):

Factors favoring earlier resumption:

• High thromboembolic risk:
  • Mechanical heart valve (especially mitral)
  • High CHA2DS2-VASc score (≥4)
  • Recent VTE
  • Previous cardioembolic stroke
• Lobar ICH (lower recurrence risk than deep)
• Good functional recovery
• Bleeding controlled, no ongoing risk factors

Factors favoring delayed or no resumption:

• ICH characteristics:
  • Deep location (basal ganglia, brainstem)
  • Multiple cerebral microbleeds on MRI
  • Large hematoma volume
  • Persistent mass effect
• High bleeding risk:
  • Uncontrolled hypertension
  • Cerebral amyloid angiopathy
  • Advanced age
• Poor neurological outcome/comfort care

Timing guidance:

• Most guidelines: 4-8 weeks after ICH
• Individualized risk-benefit assessment essential
• Multidisciplinary discussion (neurology, hematology, cardiology, patient)
• Consider left atrial appendage closure as alternative for AF patients

---

SAQ 2: DOAC-Associated Major Bleeding

Question: A 68-year-old man on rivaroxaban 20 mg daily for atrial fibrillation presents with melena, hemodynamic instability (BP 85/50), and hemoglobin 72 g/L. His last rivaroxaban dose was 6 hours ago.

(a) Describe your approach to laboratory assessment of anticoagulation status in this patient. (3 marks) (b) Outline the reversal options for rivaroxaban-associated life-threatening bleeding, including doses. (5 marks) (c) What are the key findings from the ANNEXA-4 trial and how do they inform management? (4 marks)

Model Answer:

(a) Laboratory assessment (3 marks):

Standard coagulation tests:

• PT/INR: May be prolonged with rivaroxaban, but normal PT does NOT exclude therapeutic levels
• aPTT: Usually normal or slightly prolonged; insensitive
• Thrombin time: Normal (not affected by Xa inhibitors)

Specific assays:

• Anti-Xa activity (rivaroxaban-specific): Gold standard for quantification
  • Measures drug concentration directly
  • Result in ng/mL; correlates with anticoagulant effect
  • May not be available urgently in all centers

Practical considerations:

• Given life-threatening bleeding 6 hours post-dose, assume significant drug levels present
• Do not delay reversal for laboratory confirmation
• Baseline samples for later analysis if specific assays unavailable immediately

(b) Reversal options (5 marks):

First-line: Andexanet alfa (if available)

Given: Rivaroxaban greater than 10 mg (20 mg), last dose ≤8 hours ago → High-dose regimen

• Loading dose: 800 mg IV bolus over 15-30 minutes
• Maintenance infusion: 8 mg/min for 2 hours (960 mg total)
• Total dose: 1760 mg

Mechanism: Recombinant modified factor Xa; binds and sequesters rivaroxaban

Second-line: 4-Factor PCC (if andexanet unavailable)

• Dose: 50 U/kg IV (maximum 5000 U)
• Mechanism: Provides procoagulant factors to overwhelm Xa inhibitor effect
• Does not directly reverse drug, but restores hemostatic capacity
• Faster and more available than andexanet; similar mortality outcomes (ANNEXA-I)

Adjunctive measures:

• TXA 1 g IV loading + 1 g over 8 hours (antifibrinolytic support)
• Activated charcoal 50 g if additional doses ingested below 2-4 hours
• Supportive care:
  • Blood product resuscitation (target Hb, fibrinogen greater than 1.5 g/L, platelets greater than 50)
  • Correct hypothermia, acidosis
  • Early gastroenterology for endoscopy

(c) ANNEXA-4 trial findings (4 marks):

Study design:

• Prospective, open-label, single-arm trial
• 352 patients with major bleeding on Xa inhibitors (apixaban or rivaroxaban primarily)
• 67% had intracranial hemorrhage

Key findings:

Efficacy:

• Median anti-Xa activity reduction: 92% for both drugs
• Hemostatic efficacy (excellent/good) at 12 hours: 82%
• Rapid onset: Effect seen within minutes of bolus completion

Safety concerns:

• Thrombotic events: 10% within 30 days (stroke, MI, DVT, PE)
• 30-day mortality: 14%

Clinical implications:

1. Andexanet effectively reverses anticoagulant effect and achieves hemostasis
2. Significant thrombotic risk necessitates careful patient selection
3. No survival benefit compared to PCC has been demonstrated (ANNEXA-I)
4. Very high cost limits availability
5. PCC is a reasonable alternative, especially given similar mortality outcomes

Critical appraisal:

• Single-arm design limits conclusions about comparative efficacy
• ANNEXA-I randomized data suggests similar mortality to PCC
• Higher thrombotic risk with andexanet than PCC in ANNEXA-I
• Cost-effectiveness favors PCC in many healthcare systems

---

Viva Scenarios

Viva 1: Dabigatran Reversal for Emergency Surgery

Examiner: A 75-year-old man on dabigatran 150 mg BD for AF presents with acute appendicitis requiring laparoscopic appendicectomy. His last dose was 4 hours ago. His creatinine is 180 μmol/L (eGFR 35 mL/min). Tell me about your approach.

Candidate response:

This is a patient on dabigatran requiring semi-urgent surgery with recent drug ingestion and renal impairment, which prolongs dabigatran half-life.

Risk assessment:

Time since last dose: 4 hours → peak drug levels likely Renal function: eGFR 35 → half-life extended to 18-24+ hours Surgery timing: Semi-urgent; ideally delay 24-48 hours if possible

Management options:

1. If surgery can be delayed 24-48 hours:

   • Withhold dabigatran
   • Allow drug clearance (may need 3-4 half-lives = 72-96 hours given renal impairment)
   • Check dTT or aPTT before surgery

2. If surgery required within 12-24 hours:

   • Idarucizumab 5 g IV (two 2.5 g boluses)
   • Provides immediate, complete reversal
   • No dose adjustment for renal impairment
   • Proceed to surgery after administration

Examiner: What if idarucizumab is not available?

Candidate response:

Alternative strategies:

1. Hemodialysis: Dabigatran is 80% unbound to protein and dialyzable

   • 4-hour hemodialysis removes ~60% of drug
   • Requires vascular access and time
   • May be reasonable if surgery can wait 4-6 hours

2. Activated PCC (FEIBA) 50-80 U/kg:

   • May provide some hemostatic benefit
   • Higher thrombotic risk
   • Less evidence than for Xa inhibitors

3. 4-Factor PCC 50 U/kg:

   • Provides procoagulant support
   • Less effective for dabigatran than Xa inhibitors
   • Consider as adjunct

4. Proceed with meticulous surgical hemostasis:

   • Accept increased bleeding risk
   • Have blood products available
   • TXA as adjunct

Examiner: The surgery proceeds with idarucizumab. Post-operatively the patient develops fever and right iliac fossa pain. CT shows DVT. How do you manage this?

Candidate response:

This is a recognized complication following anticoagulant reversal—thrombosis due to the prothrombotic state created by reversal plus underlying thrombotic risk.

Management:

1. Confirm diagnosis: Doppler ultrasound if DVT uncertain; CT venogram if iliofemoral suspected

2. Risk assessment: Balance recurrent bleeding risk vs extension/PE risk

   • Appendicectomy is low bleeding risk surgery
   • 24-48 hours post-op, most surgical bleeding risk has passed

3. Restart anticoagulation:

   • If hemostasis assured, restart anticoagulation
   • Options: LMWH, dabigatran (can restart after idarucizumab wears off at 24 hours), or alternative DOAC
   • Given recent thrombosis, would restart anticoagulation promptly

4. IVC filter: Consider only if anticoagulation absolutely contraindicated

   • Not routine; associated with long-term complications

Key teaching point: Thrombotic events occur in 5-10% of patients after reversal. This is primarily due to the underlying thrombotic risk factor (AF in this case), not the reversal agent itself. Early resumption of anticoagulation when safe is important.

---

Viva 2: Warfarin Reversal and Perioperative Bridging

Examiner: An 80-year-old woman with a mechanical mitral valve on warfarin presents for elective hip replacement. Her INR is 3.1. How would you manage her perioperatively?

Candidate response:

This is a high-risk scenario requiring careful perioperative anticoagulation management. Mechanical mitral valves have the highest thrombotic risk among VKA indications.

Preoperative management:

1. Stop warfarin 5-7 days before surgery

   • Longer duration given elderly (slower metabolism) and higher INR

2. Bridging anticoagulation:

   • This patient DOES warrant bridging (unlike most AF patients per BRIDGE trial)
   • Mechanical mitral valve is high-risk (not studied in BRIDGE)
   • Start LMWH when INR below 2.0 (typically day 3-4 after stopping warfarin)
   • Therapeutic dose: enoxaparin 1 mg/kg BD or 1.5 mg/kg daily

3. Last dose of LMWH:

   • Stop 24 hours before surgery (last therapeutic dose 48 hours before for BD dosing)
   • Some give half-dose 24 hours before

4. Confirm INR below 1.5 day before surgery

Examiner: What if she presents on the day of surgery with INR 2.5?

Candidate response:

Options depend on surgical urgency:

1. If surgery can be delayed 24-48 hours:

   • Vitamin K 2-5 mg oral or IV
   • Repeat INR and proceed when below 1.5

2. If surgery semi-urgent (within 12-24 hours):

   • Vitamin K 5-10 mg IV
   • Consider low-dose PCC (10-15 U/kg) to accelerate reversal
   • Recheck INR at 6 hours

3. If surgery emergent:

   • 4F-PCC 25 U/kg + Vitamin K 10 mg IV
   • Achieves rapid reversal
   • Proceed when INR confirmed below 1.5

Examiner: The BRIDGE trial showed bridging increases bleeding. Why are you bridging this patient?

Candidate response:

Excellent point. The BRIDGE trial was pivotal, but its conclusions do not apply to mechanical heart valves:

BRIDGE trial limitations:

• Studied AF patients only (CHA2DS2-VASc average ~3)
• EXCLUDED mechanical heart valves
• EXCLUDED recent stroke/TIA (below 12 weeks)
• Mean CHADS2 score was 2.3 (moderate risk)

Why mechanical mitral valve is different:

• Annual thromboembolic risk 4-12% without anticoagulation
• Higher than most AF patients
• Thrombus on valve can cause catastrophic stroke or valve dysfunction
• Guidelines (ACC/AHA, ESC) recommend bridging for mechanical valves

Risk-benefit:

• Accept higher bleeding risk (2-3x per BRIDGE)
• Thromboembolic consequences potentially catastrophic
• Bleeding from hip surgery is usually manageable; stroke is not

Alternative approach:

• Some centers now use shorter bridging intervals
• Some use half-dose LMWH
• Individualized discussion with patient and cardiology

---

Viva 3: TXA and Antifibrinolytics

Examiner: A trauma patient arrives with massive hemorrhage following a motorcycle accident. Tell me about the role of tranexamic acid.

Candidate response:

TXA is an essential component of trauma resuscitation for hemorrhage control.

Mechanism:

• Lysine analogue that binds plasminogen
• Prevents plasminogen activation to plasmin
• Inhibits fibrinolysis, stabilizing clot

CRASH-2 trial evidence (PMID: 20554319):

• 20,211 trauma patients across 40 countries
• TXA 1 g loading + 1 g over 8 hours
• Results:
  • "All-cause mortality: 14.5% vs 16.0% (NNT ~67)"
  • "Death from bleeding: 4.9% vs 5.7%"
  • No increase in thromboembolic events

Critical timing:

• Maximum benefit if given within 1 hour of injury
• Still beneficial if given within 3 hours
• Harmful if given after 3 hours (increased mortality from bleeding)

Current recommendations:

• Give TXA 1 g IV as soon as possible in significant trauma
• Second gram over 8 hours
• Do not wait for laboratory evidence of hyperfibrinolysis
• Part of massive transfusion protocol at many centers

Examiner: What about TXA for gastrointestinal bleeding?

Candidate response:

The evidence for GI bleeding is different and less compelling than trauma.

HALT-IT trial (PMID: 32563232):

• 12,009 patients with significant upper GI bleeding
• TXA 1 g + 3 g over 24 hours vs placebo
• Results:
  • No reduction in death from GI bleeding (3.7% vs 3.8%)
  • No reduction in rebleeding
  • Increased venous thromboembolic events (0.8% vs 0.4%)

Why different from trauma?

• GI bleeding pathophysiology different (variceal, ulcer, etc.)
• Hemostasis achieved by endoscopic intervention, not clot stability
• Higher baseline thrombotic risk population

Current recommendation:

• TXA NOT routinely recommended for GI bleeding
• May have role in specific circumstances (massive hemorrhage, delayed endoscopy)
• Endoscopic therapy is the priority

---

Viva 4: Heparin Reversal and Complications

Examiner: A patient has just come off cardiopulmonary bypass and is bleeding excessively. The ACT is 180 seconds (baseline 120). How do you approach this?

Candidate response:

Post-CPB bleeding with elevated ACT suggests residual heparinization requiring protamine and systematic evaluation.

Immediate assessment:

1. Surgical bleeding vs coagulopathy:

   • Diffuse bleeding suggests coagulopathy
   • Focal bleeding suggests surgical source
   • Communicate with surgeon

2. Laboratory evaluation:

   • ACT, aPTT
   • Fibrinogen
   • Platelet count
   • Viscoelastic testing (TEG/ROTEM) if available

Protamine for residual heparin:

ACT 180 (elevated from 120) suggests residual heparin effect.

Dosing:

• Empiric: Protamine 25-50 mg IV
• Calculated: Based on heparin dose in circuit and recent boluses
• Recheck ACT after 5-10 minutes

Administration:

• Give slowly over 10+ minutes
• Rapid administration causes hypotension, bradycardia, pulmonary hypertension

Examiner: You give protamine 50 mg and the patient develops hypotension and bronchospasm. What is happening?

Candidate response:

This is a protamine reaction, which can manifest as:

Type I (Hypotension):

• Most common
• Histamine release, direct vasodilation
• Usually mild, responds to slowing infusion
• May need vasopressors

Type II (Anaphylactoid/Anaphylaxis):

• True IgE-mediated anaphylaxis
• Bronchospasm, hypotension, urticaria
• Risk factors: Fish allergy, previous protamine, NPH insulin use, vasectomy (anti-sperm antibodies cross-react)

Type III (Catastrophic pulmonary vasoconstriction):

• Rare but severe
• Acute right heart failure
• Protamine-heparin complexes activate complement
• May require ECMO support

Management of this reaction:

1. Stop protamine infusion
2. Epinephrine 10-100 mcg IV boluses (titrate to response)
3. Bronchodilators: Salbutamol nebulized
4. Antihistamines: Promethazine 25 mg IV
5. Hydrocortisone 200 mg IV
6. Volume resuscitation
7. Vasopressors (norepinephrine) if refractory hypotension
8. Mechanical support (IABP, ECMO) if catastrophic

Prevention:

• Slow administration always
• Identify high-risk patients preoperatively
• Consider avoiding protamine in severe fish allergy (accept residual heparin, use alternative hemostatic strategies)

---

References

1. Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(3):623-627. PMID: 26911798

2. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. J Am Coll Cardiol. 2020;76(5):594-622. PMID: 32680646

3. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234-1243. PMID: 23906331

4. Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15(6):566-573. PMID: 27178157

5. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin. Circulation. 2001;103(24):2994-3018. PMID: 11413093

6. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg. 1999;88(2):312-319. PMID: 9972747

7. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373(6):511-520. PMID: 26559317

8. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;377(5):431-441. PMID: 28693366

9. Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019;380(14):1326-1335. PMID: 30730852

10. Milling TJ Jr, Middeldorp S, Weitz JI, et al. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2024;390(17):1531-1541. PMID: 38747214

11. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. PMID: 20554319

12. Hickey M, Gatien M, Taljaard M, et al. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation. 2013;128(4):360-364. PMID: 23770748

13. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S-e43S. PMID: 22315264

14. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015;373(9):823-833. PMID: 26095867

15. CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101. PMID: 21439633

16. Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077-2087. PMID: 25728933

17. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824-836. PMID: 25710659

18. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S-198S. PMID: 18574265

19. Stangier J, Rathgen K, Stähle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303. PMID: 17506785

20. Weitz JI, Eikelboom JW. Urgent need to measure effects of direct oral anticoagulants. Circulation. 2016;134(3):186-188. PMID: 27436877

21. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1128-1139. PMID: 25212648

22. Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018;118(3):437-450. PMID: 29433148

23. Lubetsky A, Yonath H, Olchovsky D, et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163(20):2469-2473. PMID: 14609783

24. Dentali F, Marchesi C, Giorgi Pierfranceschi M, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011;106(3):429-438. PMID: 21800002

25. Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011;154(8):529-540. PMID: 21502651

26. Horrow JC. Protamine: a review of its toxicity. Anesth Analg. 1985;64(3):348-361. PMID: 3883848

27. Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol. 2015;35(8):1736-1745. PMID: 26088570

28. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-1127. PMID: 20352166

29. Amstutz U, Shams M, Gershon A, et al. Comparative effectiveness of andexanet alfa vs prothrombin complex concentrate for factor Xa inhibitor-associated intracranial hemorrhage: A systematic review and meta-analysis. J Thromb Haemost. 2023;21(8):2076-2090. PMID: 37257218

30. Schulman S, Gross PL, Engström M, et al. Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study. Thromb Haemost. 2018;118(5):842-851. PMID: 29702691

31. Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014;14(2):147-154. PMID: 24277644

32. Ker K, Edwards P, Perel P, et al. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054. PMID: 22611164

33. Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019;23(1):98. PMID: 30917843

34. Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6-46. PMID: 26714677

35. Barkun AN, Almadi M, Kuipers EJ, et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Ann Intern Med. 2019;171(11):805-822. PMID: 31634917

36. Raval AN, Cigarroa JE, Chung MK, et al. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation. 2017;135(10):e604-e633. PMID: 28167634

37. Keeling D, Tait RC, Watson H; British Committee for Standards in Haematology. Peri-operative management of anticoagulation and antiplatelet therapy. Br J Haematol. 2016;175(4):602-613. PMID: 27714755

38. Murthy SB, Gupta A, Merkler AE, et al. Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Stroke. 2017;48(6):1594-1600. PMID: 28416625

39. Lutz J, Menke J, Sollinger D, et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014;29(1):29-40. PMID: 24132242

40. Intagliata NM, Argo CK, Stine JG, et al. Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost. 2018;118(8):1491-1506. PMID: 30060252

41. Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021;19(8):1874-1882. PMID: 34259389

42. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S-e350S. PMID: 22315266

43. Connors JM. Testing and monitoring direct oral anticoagulants. Blood. 2018;132(19):2009-2015. PMID: 30228232

---

Algorithm: Anticoagulant Reversal Decision Pathway

Step 1: Identify the Anticoagulant

Determine which anticoagulant the patient is taking:

Step 2: Assess Bleeding Severity

Step 3: Select Reversal Strategy

Life-threatening or Major Bleeding:

Clinically Relevant Non-Major or Minor Bleeding:

• Consider withholding anticoagulant only
• Supportive care (local hemostasis, transfusion PRN)
• Reassess if bleeding escalates
• Full reversal usually not indicated

Step 4: Adjunctive Measures

For all significant bleeding:

• Tranexamic acid 1 g IV (if within 3 hours for trauma)
• Maintain fibrinogen greater than 1.5 g/L
• Maintain platelets greater than 50 x 10^9/L (greater than 100 for CNS)
• Correct hypothermia and acidosis
• Source control where possible

Step 5: Post-Reversal Management

1. Monitor for re-bleeding (drug may return if idarucizumab/andexanet effect wanes)
2. Monitor for thrombosis (5-10% risk)
3. Plan anticoagulation resumption timing
4. Document indication for original anticoagulation

---

Formulary: Quick Reference Dosing

Vitamin K (Phytonadione)

Notes:

• IV: Dilute in 50 mL NS, infuse over 20-30 minutes
• Anaphylactoid reactions rare with slow infusion
• Must accompany PCC for sustained reversal

4-Factor Prothrombin Complex Concentrate

Administration:

• Reconstitute per manufacturer instructions
• Infuse at 3-8 mL/min (product-specific)
• Maximum rate: 210 U/min (Beriplex) or 0.12 mL/kg/min (Kcentra)

Protamine Sulfate

Maximum single dose: 50 mg Administration: Slow IV over 10 minutes

Idarucizumab (Praxbind)

Dose: 5 g IV as two 2.5 g boluses (no more than 15 minutes apart) No dose adjustment for renal impairment, age, or weight May repeat: If re-emergence of dabigatran effect or continued bleeding

Andexanet Alfa (Andexxa)

Administration:

• Bolus over 15-30 minutes
• Infusion over 2 hours
• Total treatment duration: 2.5 hours

Tranexamic Acid

Critical: Must be within 3 hours of injury (trauma)

---

Nursing Considerations

Pre-Administration Checks

For all reversal agents:

1. Confirm anticoagulant type and last dose
2. Baseline coagulation studies (do not delay treatment)
3. Check allergies (fish allergy for protamine, prior reactions)
4. Establish reliable IV access
5. Prepare for possible adverse reactions

Administration Monitoring

PCC:

• Watch for thrombotic complications
• Monitor vital signs during infusion
• Have resuscitation equipment available

Protamine:

• Slow infusion (10 minutes minimum)
• Watch for hypotension, bradycardia
• Have epinephrine and vasopressors ready
• Monitor for anaphylaxis (especially in fish allergy, previous protamine, vasectomy)

Idarucizumab:

• Can give rapid bolus
• No specific monitoring required beyond bleeding assessment

Andexanet alfa:

• Monitor for thrombosis (higher rate than other agents)
• Infusion reactions possible
• 2-hour infusion after bolus

Post-Administration Care

1. Repeat coagulation studies at appropriate intervals
2. Ongoing bleeding assessment
3. Hemodynamic monitoring
4. Watch for thrombotic complications
5. Document response to treatment
6. Communicate with medical team regarding anticoagulation plan

---

Pharmacist Pearls

Drug Interactions and Considerations

Vitamin K:

• Effects warfarin resistance for 1-2 weeks after high doses
• Oral and IV equally effective (IV preferred in critical illness)
• Do not use IM route (hematoma risk)

PCC:

• Contains heparin in some formulations (caution in HIT)
• Store appropriately; reconstitute per manufacturer
• Relatively short shelf life once reconstituted
• Track lot numbers for pharmacovigilance

Idarucizumab:

• Room temperature stable for 48 hours
• No drug interactions
• Does not require dose adjustment
• One-time dose usually sufficient

Andexanet alfa:

• Very expensive; may require special authorization
• Binds TFPI, potentially enhancing coagulation beyond just reversing Xa inhibitor
• Monitor for thrombosis post-administration
• May need to restrict to specific indications due to cost

Formulary Management

• Develop institutional protocols for reversal agent use
• Stock appropriate agents based on institutional patterns
• Establish blood bank collaboration for PCC
• Consider cost-effectiveness in protocol development
• After-hours availability planning essential

---

Key Clinical Pearls

1. Time is brain: In ICH, give PCC immediately; do not wait for INR result
2. Vitamin K is not optional: Always give with PCC for VKA reversal; without it, anticoagulation recurs
3. DOACs are short-acting: If last dose greater than 48 hours ago and renal function normal, drug effect may be minimal
4. Normal PT does not exclude Xa inhibitor effect: Especially apixaban—use drug-specific anti-Xa assays
5. Protamine can cause anticoagulation: Excess protamine binds clotting factors; use calculated doses
6. Bridging is usually harmful: Per BRIDGE trial, avoid in most AF patients
7. TXA timing is critical: greater than 3 hours after trauma increases mortality
8. Thrombosis follows reversal: 5-10% risk; plan anticoagulation resumption
9. Andexanet is not proven better than PCC: ANNEXA-I showed similar mortality but higher thrombosis with andexanet
10. PCC is the workhorse: Available, affordable, effective for VKAs and Xa inhibitors

---

Australian Context

PBS and TGA Considerations

Idarucizumab (Praxbind):

• TGA approved for dabigatran reversal
• Available in major centers
• Cost approximately $4,000-5,000 per treatment

Andexanet alfa:

• TGA provisional approval (pending further review)
• Limited availability; restricted to major tertiary centers
• Very high cost (~$25,000-50,000 per treatment)
• Many institutions use PCC as first-line due to cost and similar outcomes

4-Factor PCC:

• Available as Beriplex (CSL Behring) and Prothrombinex-VF (CSL)
• Prothrombinex-VF is a 3-factor PCC (low factor VII); Beriplex is 4-factor
• Ensure appropriate product selection

Blood Service Coordination

• Contact Australian Red Cross Lifeblood for PCC supply
• After-hours access protocols should be established
• Track usage for national pharmacovigilance

State Guidelines

Various Australian jurisdictions have specific anticoagulant reversal guidelines:

• NSW Health: Emergency Department Management of Anticoagulant Bleeding
• Victoria: Clinical Practice Guideline for Anticoagulant Reversal
• Queensland: Statewide Clinical Guidelines

Institutions should adapt national guidance to local formulary and availability.